Goldman Urology has recently introduced 'UROSTONE,' a next-generation extracorporeal shockwave lithotripter that incorporates the latest artificial intelligence (AI) technology.
This device is a urinary stone treatment system equipped with both an AI breathing trigger system and an AI auto-focusing function, both of which are domestically patented technologies. It is highly regarded for significantly enhancing both precision and efficiency in the treatment of urinary stones.
Conventional extracorporeal shockwave lithotripters have faced limitations: if the position of the stone subtly shifted due to changes in the patient's breathing, the shockwave's point of impact would deviate, resulting in decreased lithotripsy efficiency. In contrast, UROSTONE is equipped with a respiration-linked targeting system. This system utilizes AI to analyze the patient's breathing patterns in real-time and track even the most minute movements of the stone, automatically readjusting the shockwave's trajectory. As a result, the shockwave can consistently strike the center of the stone, leading to a significant improvement in lithotripsy efficiency and a reduction in procedure time.
Furthermore, it boasts the only auto-focusing function in Korea, which is based on AI image recognition technology. This feature allows the system to autonomously analyze and adjust the stone's position and focal point, thereby maximizing the accuracy of the procedure.
An official from Goldman Urology stated, "Because AI simultaneously detects both the patient's breathing and the movement of the stone, automatically adjusting the optimal shockwave, it enables more precise and safer lithotripsy." The official added, "We anticipate a high level of patient satisfaction, as the procedure time is reduced, and the burden of pain and the need for re-treatment are significantly decreased."